A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
| Condition | Melanoma |
|---|---|
| Phase | Phase 1/2 |
| Sponsor | Jennerex Biotherapeutics |
| Status | Completed |
| Enrollment | 10 participants |
| Interventions | JX-594 |
| Start date | Feb, 2007 |
| Completion date | Feb, 2008 |
| Results posted | Jul 27, 2026 |
Summary
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
Number of Participants With Objective Response in Injected Tumor(s)
| Recombinant Vaccinia Virus JX-594 | 5 Participants with Stable disease |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)